MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock in public...
$539,776K
Proceeds from
convertible senior notes
$223,100K
Proceeds from issuance of
common stock under atm,...
$159,323K
Proceeds from long-term
debt
$49,291K
Proceeds from issuance of
common stock upon stock...
$11,546K
Proceeds from issuance of
stock from employee...
$1,350K
Net cash provided by
financing activities
$878,233K
Canceled cashflow
$106,153K
Net increase
(decrease) in cash, cash...
$214,263K
Canceled cashflow
$663,970K
Repayment of long-term
debt
$54,635K
Taxes paid related to
net share...
$48,896K
Payment of debt issuance
costs
$2,622K
Maturities and sales of
marketable securities
$289,199K
Stock-based compensation
expense
$46,079K
Accrued expenses and
other current...
$10,686K
Loss on debt
extinguishment
-$7,181K
Depreciation expense
$2,564K
Amortization of right-of-use
operating lease assets
$2,019K
Other assets
-$1,561K
Amortization of debt discount
and issuance costs
$601K
Other liabilities
$33K
Net cash provided by
(used in) investing...
-$399,526K
Net cash used in
operating activities
-$264,444K
Canceled cashflow
$289,199K
Canceled cashflow
$70,724K
Purchases of marketable
securities
$687,171K
Net loss
-$328,937K
Purchases of property and
equipment
$1,554K
Accounts payable
-$2,509K
Net amortization
(accretion) of premiums...
$1,962K
Operating lease liability
-$1,565K
Prepaid expenses and
other current assets
$195K
Back
Back
Cash Flow
source: myfinsight.com
Cogent Biosciences, Inc. (COGT)
Cogent Biosciences, Inc. (COGT)